Jae-Sung Yi1, Sravan Perla2, Yan Huang3, Kana Mizuno4, Frank J Giordano3, Alexander A Vinks4,5, Anton M Bennett2,6. 1. Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA. jae-sung.yi@yale.edu. 2. Department of Pharmacology, Yale University School of Medicine, New Haven, CT, 06520, USA. 3. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA. 4. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 5. Department of Pediatrics, University of Cincinnati, College of Medicine, Cincinnati, OH, USA. 6. Program in Integrative Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, New Haven, CT, 06520, USA.
Abstract
PURPOSE: Noonan syndrome with multiple lentigines (NSML) is an autosomal dominant disorder presenting with hypertrophic cardiomyopathy (HCM). Up to 85% of NSML cases are caused by mutations in the PTPN11 gene that encodes for the Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2). We previously showed that low-dose dasatinib protects from the development of cardiac fibrosis in a mouse model of NSML harboring a Ptpn11Y279C mutation. This study is performed to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a low-dose of dasatinib in NSML mice and to determine its effectiveness in ameliorating the development of HCM. METHODS: Dasatinib was administered intraperitoneally into NSML mice with doses ranging from 0.05 to 0.5 mg/kg. PK parameters of dasatinib in NSML mice were determined. PD parameters were obtained for biochemical analyses from heart tissue. Dasatinib-treated NSML mice (0.1 mg/kg) were subjected to echocardiography and assessment of markers of HCM by qRT-PCR. Transcriptome analysis was performed from the heart tissue of low-dose dasatinib-treated mice. RESULTS: Low-dose dasatinib exhibited PK properties that were linear across doses in NSML mice. Dasatinib treatment of between 0.05 and 0.5 mg/kg in NSML mice yielded an exposure-dependent inhibition of c-Src and PZR tyrosyl phosphorylation and inhibited AKT phosphorylation. We found that doses as low as 0.1 mg/kg of dasatinib prevented HCM in NSML mice. Transcriptome analysis identified differentially expressed HCM-associated genes in the heart of NSML mice that were reverted to wild type levels by low-dose dasatinib administration. CONCLUSION: These data demonstrate that low-dose dasatinib exhibits desirable therapeutic PK properties that is sufficient for effective target engagement to ameliorate HCM progression in NSML mice. These data demonstrate that low-dose dasatinib treatment may be an effective therapy against HCM in NSML patients.
PURPOSE: Noonan syndrome with multiple lentigines (NSML) is an autosomal dominant disorder presenting with hypertrophic cardiomyopathy (HCM). Up to 85% of NSML cases are caused by mutations in the PTPN11 gene that encodes for the Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2). We previously showed that low-dose dasatinib protects from the development of cardiac fibrosis in a mouse model of NSML harboring a Ptpn11Y279C mutation. This study is performed to determine the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a low-dose of dasatinib in NSML mice and to determine its effectiveness in ameliorating the development of HCM. METHODS: Dasatinib was administered intraperitoneally into NSML mice with doses ranging from 0.05 to 0.5 mg/kg. PK parameters of dasatinib in NSML mice were determined. PD parameters were obtained for biochemical analyses from heart tissue. Dasatinib-treated NSML mice (0.1 mg/kg) were subjected to echocardiography and assessment of markers of HCM by qRT-PCR. Transcriptome analysis was performed from the heart tissue of low-dose dasatinib-treated mice. RESULTS: Low-dose dasatinib exhibited PK properties that were linear across doses in NSML mice. Dasatinib treatment of between 0.05 and 0.5 mg/kg in NSML mice yielded an exposure-dependent inhibition of c-Src and PZR tyrosyl phosphorylation and inhibited AKT phosphorylation. We found that doses as low as 0.1 mg/kg of dasatinib prevented HCM in NSML mice. Transcriptome analysis identified differentially expressed HCM-associated genes in the heart of NSML mice that were reverted to wild type levels by low-dose dasatinib administration. CONCLUSION: These data demonstrate that low-dose dasatinib exhibits desirable therapeutic PK properties that is sufficient for effective target engagement to ameliorate HCM progression in NSML mice. These data demonstrate that low-dose dasatinib treatment may be an effective therapy against HCM in NSML patients.
Authors: Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis Journal: J Clin Invest Date: 2011-02-21 Impact factor: 14.808
Authors: Wiljan J A J Hendriks; Ari Elson; Sheila Harroch; Rafael Pulido; Andrew Stoker; Jeroen den Hertog Journal: FEBS J Date: 2012-10-01 Impact factor: 5.542
Authors: Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb Journal: Am J Hum Genet Date: 2002-05-01 Impact factor: 11.025
Authors: Mary Ella Pierpont; Craig T Basson; D Woodrow Benson; Bruce D Gelb; Therese M Giglia; Elizabeth Goldmuntz; Glenn McGee; Craig A Sable; Deepak Srivastava; Catherine L Webb Journal: Circulation Date: 2007-05-22 Impact factor: 29.690
Authors: Mylène Tajan; Aurélie Batut; Thomas Cadoudal; Simon Deleruyelle; Sophie Le Gonidec; Céline Saint Laurent; Maëlle Vomscheid; Estelle Wanecq; Karine Tréguer; Audrey De Rocca Serra-Nédélec; Claire Vinel; Marie-Adeline Marques; Joffrey Pozzo; Oksana Kunduzova; Jean-Pierre Salles; Maithé Tauber; Patrick Raynal; Hélène Cavé; Thomas Edouard; Philippe Valet; Armelle Yart Journal: Proc Natl Acad Sci U S A Date: 2014-10-06 Impact factor: 11.205
Authors: Hassan Reda Hassan Elsayed; Randa El-Gamal; Mohammed R Rabei; Mona G Elhadidy; Shereen Hamed; Basma H Othman; Mohamed Mahmoud Abdelraheem Elshaer; Mostafa Khaled Sedky; Ahmed Tarek Abd Elbaset Hassan; Mohammad El-Nablaway Journal: Cells Date: 2022-02-21 Impact factor: 6.600
Authors: Maria I Kontaridis; Amy E Roberts; Lisa Schill; Lisa Schoyer; Beth Stronach; Gregor Andelfinger; Yoko Aoki; Marni E Axelrad; Annette Bakker; Anton M Bennett; Alberto Broniscer; Pau Castel; Caitlin A Chang; Lukas Cyganek; Tirtha K Das; Jeroen den Hertog; Emilia Galperin; Shruti Garg; Bruce D Gelb; Kristiana Gordon; Tamar Green; Karen W Gripp; Maxim Itkin; Maija Kiuru; Bruce R Korf; Jeff R Livingstone; Alejandro López-Juárez; Pilar L Magoulas; Sahar Mansour; Theresa Milner; Elisabeth Parker; Elizabeth I Pierpont; Kevin Plouffe; Katherine A Rauen; Suma P Shankar; Shane B Smith; David A Stevenson; Marco Tartaglia; Richard Van; Morgan E Wagner; Stephanie M Ware; Martin Zenker Journal: Am J Med Genet A Date: 2022-03-09 Impact factor: 2.578